Рамантамиг
RamantamigМНН
Prop. INN (наименование, предложенное ВОЗ)
CAS
2988886-91-3
Химическое название
immunoglobulin (H-gamma1-scFvkh_L-lambda2)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], anti-[Homo sapiens GPRC5D (G protein-coupled receptor class C group 5 member D)] and anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)], Homo sapiens monoclonal antibody; trispecific, trivalent;
H-gamma1 heavy chain anti-CD3E fused to a scFvkh anti-GPRC5D (1-721) [H-gamma1 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438), Y116>F (439) (344-448), CHS (449-450)) (121-450)] -20-mer tetrakis(tetraglycyl-seryl) linker (451-470) -scFvkh anti-GPRC5D Homo sapiens (471-721) [V-KAPPA (Homo sapiens IGKV2-24*01 (99.0%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (497-507.525-527.564-572)) (471-582) -20-mer (GGSEGKSSGSGSESKSTGGS) linker (583-602) -VH (Homo sapiens IGHV2-26*04 (93.9%) -IGHD -IGHJ6*01 (100%), CDR-IMGT [10.7.11] (628-637.655-661.700-710)) (603-721)]]; (223-215')-disulfide with L-lambda2 light chain anti-CD3E Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*02 (84.8%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.10] (26'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGLC2*01 (100%) (C-LAMBDA2) (111'-216')];
fused heavy chain scFvkh-G1(h-CH2-CH3) anti-TNFRSF17 Homo sapiens (1''-484'') [scFvkh anti-TNFRSF17 Homo sapiens (1''-252'') [V-KAPPA (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ2*01 (100%), CDR-IMGT [7.3.10] (27''-33''.51''-53''.90''-99'')) (1''-109'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (110''-129'') -[VH (Homo sapiens IGHV3-23*01 (100%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.16] (155''-162''.180''-187''.226''-241'')) (130''-252'')] -Homo sapiens IGHG1*03v h-CH2-CH3-CHS, nG1m1 CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob), 15-G1v37 hinge S5 [(hinge 1-15 C5>S (257'') (253''-267''), CH2 L1.3>A (271''), L1.2>A (272''), D27>S (302'') (268''-377''), CH3 E12 (393''), M14 (395''), T22>W (403'') (378''-482''), CHS (483''-484'')) (253''-484'')]]; dimer (229-263'': 232-266'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
H-gamma1 heavy chain anti-CD3E fused to a scFvkh anti-GPRC5D (1-721) [H-gamma1 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438), Y116>F (439) (344-448), CHS (449-450)) (121-450)] -20-mer tetrakis(tetraglycyl-seryl) linker (451-470) -scFvkh anti-GPRC5D Homo sapiens (471-721) [V-KAPPA (Homo sapiens IGKV2-24*01 (99.0%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (497-507.525-527.564-572)) (471-582) -20-mer (GGSEGKSSGSGSESKSTGGS) linker (583-602) -VH (Homo sapiens IGHV2-26*04 (93.9%) -IGHD -IGHJ6*01 (100%), CDR-IMGT [10.7.11] (628-637.655-661.700-710)) (603-721)]]; (223-215')-disulfide with L-lambda2 light chain anti-CD3E Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*02 (84.8%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.10] (26'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGLC2*01 (100%) (C-LAMBDA2) (111'-216')];
fused heavy chain scFvkh-G1(h-CH2-CH3) anti-TNFRSF17 Homo sapiens (1''-484'') [scFvkh anti-TNFRSF17 Homo sapiens (1''-252'') [V-KAPPA (Homo sapiens IGKV3-20*01 (94.8%) -IGKJ2*01 (100%), CDR-IMGT [7.3.10] (27''-33''.51''-53''.90''-99'')) (1''-109'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (110''-129'') -[VH (Homo sapiens IGHV3-23*01 (100%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.16] (155''-162''.180''-187''.226''-241'')) (130''-252'')] -Homo sapiens IGHG1*03v h-CH2-CH3-CHS, nG1m1 CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob), 15-G1v37 hinge S5 [(hinge 1-15 C5>S (257'') (253''-267''), CH2 L1.3>A (271''), L1.2>A (272''), D27>S (302'') (268''-377''), CH3 E12 (393''), M14 (395''), T22>W (403'') (378''-482''), CHS (483''-484'')) (253''-484'')]]; dimer (229-263'': 232-266'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Структура

Иностранные названия
- Ramantamigum (латинское)
- Ramantamig (английское)
- Ramantamig (немецкое)
- Ramantamig (французское)
- Ramantamig (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Рамантамиг: